摘要
目的探讨低剂量聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)在预防性治疗化疗后Ⅲ/Ⅳ度骨髓抑制中的应用效果。方法选取安徽理工大学第一附属医院2022年4月至2023年9月收治的80例恶性肿瘤患者作为研究对象,随机分为对照组(n=40)和观察组(n=40)。观察组和对照组患者化疗1个周期结束后24~48 h分别给予3.0 mg和6.0 mg PEG-rhG-CSF进行皮下注射用药。观察2组用药后Ⅲ/Ⅳ度中性粒细胞减少症发生情况及持续时间、中性粒细胞缺乏伴发热(FN)及不良反应发生情况、生活质量[欧洲癌症生活质量调查问卷(EORTC QLQ-C30)]评分变化。结果用药后,2组Ⅲ/Ⅳ度中性粒细胞减少症、FN发生率比较差异无统计学意义(P>0.05);全部患者中,观察组中性粒细胞水平高于对照组[(1.77±0.70)×10^(9)/L vs(1.50±0.41)×10^(9)/L,t=2.071,P=0.042]。Ⅲ/Ⅳ度中性粒细胞减少症在对照组发生1例,持续时间1 d;在观察组发生3例,持续时间2~4 d。观察组不良反应发生率低于对照组(72.50%vs 90.00%,χ^(2)=4.021,P=0.045),EORTC QLQ-C30量表各维度评分均高于对照组(P<0.05)。结论低剂量PEG-rhG-CSF在预防性治疗化疗后Ⅲ/Ⅳ度骨髓抑制的有效率与标准剂量相似,但不良反应发生率更低,患者生活质量更高。
Objective To investigate the impact of low-dose pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)on gradeⅢ/Ⅳmyelosuppression following chemotherapy.Methods A total of 80 patients with malignant tumors admitted to the First Affiliated Hospital of Anhui University of Science and Technology from April 2022 to September 2023 were selected as research subjects.The patients were randomly divided into the control group(n=40)and the observation group(n=40).The observation group and the control group received subcutaneous injections of 3.0 mg and 6.0 mg PEG-rhG-CSF,respectively,within 24 to 48 hours after chemotherapy.The incidence and duration of gradeⅢ/Ⅳneutropenia,febrile neutropenia(FN),adverse reactions,as well as changes in quality of life[European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)]scores before and after treatment were observed in both groups after medication.Results After medication,there was no significant difference in the incidence of gradeⅢ/Ⅳneutropenia or FN between the two groups(P>0.05).The observation group exhibited higher levels for neutrophils compared to control group[(1.77±0.70)×10^(9)/L vs(1.50±0.41)×10^(9)/L,t=2.071,P=0.042].GradeⅢ/Ⅳneutropenia occurred in 1 case in the control group,which lasted for 1 day,while 3 cases occurred in the observation group,which lasted for 2-4 days.Compared with the control group,the occurrence rate of adverse reactions was lower in the observation group(72.50%vs 90.00%,χ^(2)=4.021,P=0.045),and EORTC QLQ-C30 were higher for patients in the observation group(P<0.05).Conclusion Low-dose PEG-rhG-CSF demonstrates similar efficacy rates as standard doses for prophylactic managing gradeⅢ/Ⅳmyelosuppression following chemotherapy,but it exhibits a lower incidence rate of adverse reactions and improves quality-of-life of patients.
作者
王瑾
铁小伟
付宝宝
贾倩倩
王芳
李伟
WANG Jin;TIE Xiaowei;FU Baobao;JIA Qianqian;WANG Fang;LI Wei(Department of Medical Oncology,the First Affiliated Hospital of Anhui University of Science and Technology,Huainan,Anhui 232001,China;不详)
出处
《中国临床研究》
CAS
2024年第10期1547-1551,共5页
Chinese Journal of Clinical Research
基金
安徽省临床医学研究转化专项(20230429510702081)
淮南市科技计划项目(淮科规2022-72)。
关键词
中性粒细胞减少症
粒细胞集落刺激因子
重组
生活质量
化疗
骨髓抑制
Neutropenia
Granulocyte colony-stimulating factor,recombinant
Quality of life
Chemotherapy
Myelosuppression
